EMA Looks at Drug Development for Senior Population
The agency is asking for comments on a reflection paper on developing drugs for the needs of older patients.
On August 1, 2017, the European Medicines Agency (EMA) announced it was looking for public comment on a new reflection paper that takes a look at drug development specifically for senior adults. The paper asks developers to consider specific aspects of development to better suit the needs of older patients.
According to the agency, older adults may have special limitations, such as difficulty breaking a tablet by hand or having a hard time opening containers. EMA is asking drug developers to consider routes of administration, dosage forms, dosing frequency, excipients, container closure systems, devices, and user instructions that may need to be tailored to an older population. The agency is especially looking for comments regarding tablet breaking, feeding tubes, and compliance aids.
Public comment is open until Jan. 31, 2018.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
